Risk of Thrombosis With the Use of Sirolimus-Eluting Stents for Percutaneous Coronary Intervention (from Registry and Clinical Trial Data)
- 15 June 2005
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 95 (12) , 1469-1472
- https://doi.org/10.1016/j.amjcard.2005.02.015
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: A meta-analysisJournal of the American College of Cardiology, 2005
- Sirolimus-Eluting vs Uncoated Stents for Prevention of Restenosis in Small Coronary ArteriesJAMA, 2004
- A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stentsThe Lancet, 2004
- Drug-eluting stents: an early systematic review to inform policy*1, *2European Heart Journal, 2004
- The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS)Journal of the American College of Cardiology, 2004
- Analysis of 1-Year Clinical Outcomes in the SIRIUS TrialCirculation, 2004
- Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”Circulation, 2004
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary RevascularizationNew England Journal of Medicine, 2002
- Stent Thrombosis in the Modern EraCirculation, 2001